FMC-242

FMC-242 is a covalent allosteric small molecule from Frontier Medicines. A covalent allosteric inhibitor that breaks the interaction between PI3Kα and RAS, meant to block tumour signalling without affecting normal PI3Kα functions such as glucose control. The company does not state its stage; it is aimed at cancer. No clinical trial naming it is registered on ClinicalTrials.gov. No registered trial on ClinicalTrials.gov; the page gives no stage. It has not been shown to work in people.